

File downloaded on 2026-04-28

Source URL: <https://medicines.health.europa.eu/veterinary/en/600000089367>

Vetmedin 1.25 mg Chewable Tablets for Dogs

Authorised

- Pimobendan

Product identification

Medicine name:

Vetmedin 1.25 mg Chewable Tablets for Dogs

Active substance:

Pimobendan

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Pimobendan
1.25 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QC01CE90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Package description:

Cardboard box containing 50 tablets in a polyethylene bottle, closed with a polypropylene child-resistant screw cap

Cardboard box containing 100 tablets in a polyethylene bottle, closed with a polypropylene child-resistant screw cap

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

12/11/2012

Manufacturing sites for batch release:

Boehringer Ingelheim Vetmedica GmbH

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 04491/3030

Date of authorisation status change:

14/08/2024

Reference member state:

Austria

Procedure number:

AT/V/0006/001

Concerned member states:

Belgium Bulgaria Cyprus Czechia Estonia France Greece Hungary Iceland
Ireland Italy Latvia Liechtenstein Lithuania Luxembourg Netherlands Norway
Poland Portugal Romania Slovakia Slovenia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

at-puar-atv0006001-mr-vetmedin-en.pdf